Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

1.

A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response.

Krijgsman O, Roepman P, Zwart W, Carroll JS, Tian S, de Snoo FA, Bender RA, Bernards R, Glas AM.

Breast Cancer Res Treat. 2012 May;133(1):37-47. doi: 10.1007/s10549-011-1683-z. Epub 2011 Aug 4.

PMID:
21814749
[PubMed - indexed for MEDLINE]
2.

Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy.

Glück S, de Snoo F, Peeters J, Stork-Sloots L, Somlo G.

Breast Cancer Res Treat. 2013 Jun;139(3):759-67. doi: 10.1007/s10549-013-2572-4. Epub 2013 Jun 12.

PMID:
23756626
[PubMed - indexed for MEDLINE]
3.

Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.

Lips EH, Mulder L, de Ronde JJ, Mandjes IA, Vincent A, Vrancken Peeters MT, Nederlof PM, Wesseling J, Rodenhuis S.

Breast Cancer Res Treat. 2012 Feb;131(3):827-36. doi: 10.1007/s10549-011-1488-0. Epub 2011 Apr 7.

PMID:
21472434
[PubMed - indexed for MEDLINE]
4.

Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients.

Nguyen B, Cusumano PG, Deck K, Kerlin D, Garcia AA, Barone JL, Rivera E, Yao K, de Snoo FA, van den Akker J, Stork-Sloots L, Generali D.

Ann Surg Oncol. 2012 Oct;19(10):3257-63. doi: 10.1245/s10434-012-2561-6. Epub 2012 Aug 15.

PMID:
22965266
[PubMed - indexed for MEDLINE]
5.

Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.

de Ronde JJ, Hannemann J, Halfwerk H, Mulder L, Straver ME, Vrancken Peeters MJ, Wesseling J, van de Vijver M, Wessels LF, Rodenhuis S.

Breast Cancer Res Treat. 2010 Jan;119(1):119-26. doi: 10.1007/s10549-009-0499-6. Epub 2009 Aug 8.

PMID:
19669409
[PubMed - indexed for MEDLINE]
6.

Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.

Skarlos P, Christodoulou C, Kalogeras KT, Eleftheraki AG, Bobos M, Batistatou A, Valavanis C, Tzaida O, Timotheadou E, Kronenwett R, Wirtz RM, Kostopoulos I, Televantou D, Koutselini E, Papaspirou I, Papadimitriou CA, Pectasides D, Gogas H, Aravantinos G, Pavlidis N, Arapantoni P, Skarlos DV, Fountzilas G.

Cancer Chemother Pharmacol. 2012 Feb;69(2):533-46. doi: 10.1007/s00280-011-1730-9. Epub 2011 Sep 8.

PMID:
21901395
[PubMed - indexed for MEDLINE]
7.

Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.

Meyers MO, Klauber-Demore N, Ollila DW, Amos KD, Moore DT, Drobish AA, Burrows EM, Dees EC, Carey LA.

Ann Surg Oncol. 2011 Oct;18(10):2851-7. doi: 10.1245/s10434-011-1665-8. Epub 2011 Mar 26.

PMID:
21442348
[PubMed - indexed for MEDLINE]
8.

Molecular stratification of triple-negative breast cancers.

Perou CM.

Oncologist. 2010;15 Suppl 5:39-48. doi: 10.1634/theoncologist.2010-S5-39.

PMID:
21138954
[PubMed - indexed for MEDLINE]
Free Article
9.

A new gene expression signature, the ClinicoMolecular Triad Classification, may improve prediction and prognostication of breast cancer at the time of diagnosis.

Wang DY, Done SJ, McCready DR, Boerner S, Kulkarni S, Leong WL.

Breast Cancer Res. 2011 Sep 22;13(5):R92. doi: 10.1186/bcr3017.

PMID:
21939527
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features.

Venkitaraman R.

Expert Rev Anticancer Ther. 2010 Feb;10(2):199-207. doi: 10.1586/era.09.189. Review.

PMID:
20131996
[PubMed - indexed for MEDLINE]
11.

Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.

Rody A, Karn T, Gätje R, Kourtis K, Minckwitz G, Loibl S, Munnes M, Ruckhäberle E, Holtrich U, Kaufmann M, Ahr A.

Zentralbl Gynakol. 2006 Apr;128(2):76-81.

PMID:
16673249
[PubMed - indexed for MEDLINE]
12.

Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.

Bianchini G, Iwamoto T, Qi Y, Coutant C, Shiang CY, Wang B, Santarpia L, Valero V, Hortobagyi GN, Symmans WF, Gianni L, Pusztai L.

Cancer Res. 2010 Nov 1;70(21):8852-62. doi: 10.1158/0008-5472.CAN-10-1039. Epub 2010 Oct 19.

PMID:
20959472
[PubMed - indexed for MEDLINE]
Free Article
13.

Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.

Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.

Breast Cancer Res Treat. 2009 Jul;116(1):131-43. doi: 10.1007/s10549-008-0144-9. Epub 2008 Jul 31.

PMID:
18668363
[PubMed - indexed for MEDLINE]
14.

Basal vs. luminal A breast cancer subtypes: a matched case-control study using estrogen receptor, progesterone receptor, and HER-2 as surrogate markers.

Ibrahim E, Al-Gahmi AM, Zeenelin AA, Zekri JM, Elkhodary TR, Gaballa HE, Fawzy EE, El sayed ME, Alzahrani MS.

Med Oncol. 2009;26(3):372-8. doi: 10.1007/s12032-008-9131-6. Epub 2008 Nov 26.

PMID:
19034706
[PubMed - indexed for MEDLINE]
15.

Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.

Webster LR, Lee SF, Ringland C, Morey AL, Hanby AM, Morgan G, Byth K, Mote PA, Provan PJ, Ellis IO, Green AR, Lamoury G, Ravdin P, Clarke CL, Ward RL, Balleine RL, Hawkins NJ.

Clin Cancer Res. 2008 Oct 15;14(20):6625-33. doi: 10.1158/1078-0432.CCR-08-0701.

PMID:
18927304
[PubMed - indexed for MEDLINE]
Free Article
16.

RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.

Habashy HO, Powe DG, Glaab E, Ball G, Spiteri I, Krasnogor N, Garibaldi JM, Rakha EA, Green AR, Caldas C, Ellis IO.

Breast Cancer Res Treat. 2011 Jul;128(2):315-26. doi: 10.1007/s10549-010-1073-y. Epub 2010 Aug 10.

PMID:
20697807
[PubMed - indexed for MEDLINE]
17.

Molecular stratification of triple-negative breast cancers.

Perou CM.

Oncologist. 2011;16 Suppl 1:61-70. doi: 10.1634/theoncologist.2011-S1-61.

PMID:
21278442
[PubMed - indexed for MEDLINE]
Free Article
18.

HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.

Andre F, Mazouni C, Liedtke C, Kau SW, Frye D, Green M, Gonzalez-Angulo AM, Symmans WF, Hortobagyi GN, Pusztai L.

Breast Cancer Res Treat. 2008 Mar;108(2):183-90. Epub 2007 Apr 28.

PMID:
17468948
[PubMed - indexed for MEDLINE]
19.

Adjuvant chemotherapy in luminal breast cancers.

Lim E, Winer EP.

Breast. 2011 Oct;20 Suppl 3:S128-31. doi: 10.1016/S0960-9776(11)70309-5. Review.

PMID:
22015279
[PubMed - indexed for MEDLINE]
20.

Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.

Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA.

J Surg Res. 2007 Nov;143(1):109-18.

PMID:
17950079
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk